<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/E1649C06-DC81-4A08-8A23-F5B65BB6C670"><gtr:id>E1649C06-DC81-4A08-8A23-F5B65BB6C670</gtr:id><gtr:name>Babraham Institute</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>Babraham Research Campus</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB22 3AT</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E1649C06-DC81-4A08-8A23-F5B65BB6C670"><gtr:id>E1649C06-DC81-4A08-8A23-F5B65BB6C670</gtr:id><gtr:name>Babraham Institute</gtr:name><gtr:address><gtr:line1>Babraham Research Campus</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB22 3AT</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6C1616B0-6A66-4092-83FD-043B35F80C88"><gtr:id>6C1616B0-6A66-4092-83FD-043B35F80C88</gtr:id><gtr:firstName>Michael John</gtr:firstName><gtr:surname>Taussig</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BBS%2FE%2FB%2F0000S178"><gtr:id>F1C5796A-9954-453F-9333-5231E6D902E3</gtr:id><gtr:title>ProteomeBinders: A European Infrastructure of Ligand Binding Molecules against the Human Proteome</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>BBS/E/B/0000S178</gtr:grantReference><gtr:abstractText>The objective of the ProteomeBinders programme is to coordinate the establishment of a European resource infrastructure of binding molecules directed against the entire human proteome. This Coordination Action, established with funding of 1.8 million ? over 4 years by the European Commission as part of the 6th Framework Programme, brings together 26 European partners and two in the USA, including many of the foremost international leaders in all aspects of the science of binding molecules. It will be coordinated from the Babraham Institute by Dr Mike Taussig, head of the Technology Research Group and co-inventor of some key technologies for binder production and use. A major objective of the post-genome era is to detect, quantify and characterise all relevant human proteins in tissues and fluids in health and disease. This effort requires a comprehensive, characterised and standardised collection of specific protein-binding reagents, including antibodies, the most widely used such molecules, and in addition novel protein scaffolds, nucleic acid aptamers, peptides and small chemical entitities. Currently there is no pan-European platform to coordinate systematic development, resource management and quality control for these important reagents. The ProteomeBinders consortium will plan the organisation of the new European resource, by integrating existing infrastructures, reviewing technologies and high-throughput production methods, standardising tools and applications, and establishing a binders database. As well as being one of the largest genomic projects in Europe, establishing the binder resource will bring huge benefits for basic and applied research, impacting on healthcare, diagnostics, target discovery for drug intervention and therapeutics. It will thus be of great advantage to the research, medical and biotechnology communities.</gtr:abstractText><gtr:fund><gtr:end>2009-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2006-04-01</gtr:start><gtr:type>EXPENDITURE_PROJECTED</gtr:type><gtr:valuePounds>31880</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>B61EB152-F9B3-4152-B49C-744C28E797A1</gtr:id><gtr:title>Comprehensive catalog of European biobanks.</gtr:title><gtr:parentPublicationTitle>Nature biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a340e639801a1ed725f7c06ac5657ad7"><gtr:id>a340e639801a1ed725f7c06ac5657ad7</gtr:id><gtr:otherNames>Wichmann HE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1087-0156</gtr:issn><gtr:outcomeId>pm_53cbff2bff200a5da</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D2159A26-C5DD-44E8-8A66-89233E5BCE3A</gtr:id><gtr:title>European and international collaboration in affinity proteomics.</gtr:title><gtr:parentPublicationTitle>New biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3d6ae40af906653823dd69c2a5e4a55"><gtr:id>e3d6ae40af906653823dd69c2a5e4a55</gtr:id><gtr:otherNames>Stoevesandt O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1871-6784</gtr:issn><gtr:outcomeId>pm_53cc00ac00af306d6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E98D92A0-48C0-43F8-B0A8-2085BC8C21EA</gtr:id><gtr:title>Recombinant protein quality evaluation: proposal for a minimal information standard.</gtr:title><gtr:parentPublicationTitle>Standards in genomic sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21f20124357b8d950b55c5d9ceba5dfe"><gtr:id>21f20124357b8d950b55c5d9ceba5dfe</gtr:id><gtr:otherNames>Buckle AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1944-3277</gtr:issn><gtr:outcomeId>pm_53cbffbbffb9a4e55</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A9EDD3B-F047-429F-BC1B-56128AFBC6B9</gtr:id><gtr:title>In vitro protein expression: an emerging alternative to cell-based approaches.</gtr:title><gtr:parentPublicationTitle>New biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3056b899bd6dafc64c0b2150e4f403d5"><gtr:id>3056b899bd6dafc64c0b2150e4f403d5</gtr:id><gtr:otherNames>He M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1871-6784</gtr:issn><gtr:outcomeId>pm_5435b145b14341aa4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90E07782-B470-48E4-86C7-BE3DF4F922A9</gtr:id><gtr:title>Eukaryotic ribosome display with in situ DNA recovery.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3056b899bd6dafc64c0b2150e4f403d5"><gtr:id>3056b899bd6dafc64c0b2150e4f403d5</gtr:id><gtr:otherNames>He M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:isbn>978-1-61779-378-3</gtr:isbn><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>doi_53cfcbfcbf5b8ad5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1AD7D0E0-6FA4-4E81-8F2F-3B0E983A540B</gtr:id><gtr:title>Evolution of antibodies in vitro by ribosome display.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/27566a32978093bb857730ed84ca270b"><gtr:id>27566a32978093bb857730ed84ca270b</gtr:id><gtr:otherNames>Edwards BM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:isbn>978-1-61779-973-0</gtr:isbn><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>doi_53cfcbfcbfebc82c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E8F8ADEE-B251-4718-A395-A8C908C88168</gtr:id><gtr:title>Ribosome display and screening for protein therapeutics.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee82e5f889f0994bc36f1ee8f8f44d17"><gtr:id>ee82e5f889f0994bc36f1ee8f8f44d17</gtr:id><gtr:otherNames>Kastelic D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:isbn>978-1-61779-920-4</gtr:isbn><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>doi_53cfcbfcbfde90e7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C8C5F9B-1400-46C6-A288-F76A6BED364F</gtr:id><gtr:title>Cell free expression put on the spot: advances in repeatable protein arraying from DNA (DAPA).</gtr:title><gtr:parentPublicationTitle>New biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3d6ae40af906653823dd69c2a5e4a55"><gtr:id>e3d6ae40af906653823dd69c2a5e4a55</gtr:id><gtr:otherNames>Stoevesandt O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1871-6784</gtr:issn><gtr:outcomeId>pm_5435b145b142926ac</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9AEE6C9D-8DA5-49C8-BB34-67CE8DEC0815</gtr:id><gtr:title>&amp;quot;4D Biology for health and disease&amp;quot; workshop report.</gtr:title><gtr:parentPublicationTitle>New biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/591dde3290bff284fc0fe0a4c3d9b2d7"><gtr:id>591dde3290bff284fc0fe0a4c3d9b2d7</gtr:id><gtr:otherNames>Abrahams JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1871-6784</gtr:issn><gtr:outcomeId>pm_53cbfd0bfd0a910fc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BCEBC7E4-8692-4E13-8C5A-47F640573CDC</gtr:id><gtr:title>On the trail to therapeutic antibodies.</gtr:title><gtr:parentPublicationTitle>New biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5931cae12d90fde19e7034f77fd527df"><gtr:id>5931cae12d90fde19e7034f77fd527df</gtr:id><gtr:otherNames>Taussig MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1871-6784</gtr:issn><gtr:outcomeId>pm_53cbff1bff16c9a01</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BBS/E/B/0000S178</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>